- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01140607
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Primary Objectives:
- To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic impairment
- To determine the pharmacokinetics (PKs) of Cabazitaxel in patients with varying degrees of hepatic impairment
- To correlate PK variables with pharmacodynamic (PD) safety parameters in order to guide prescribers with regard to dosing in this patient population
- To assess the effect of cabazitaxel at recommended dose of 25mg/m^2 on CYP3A enzyme activity using midazolam as probe in an additional cohort of cancer patients with normal hepatic function.
Study Overview
Detailed Description
The study consists of:
- a screening phase (maximum length of 21-day).
- a treatment phase with 21-day study treatment cycles. Cycle lengths may be extended up to maximum of 12 additional days in case of unresolved toxicity.
Patients continue to receive treatment until they experience, unacceptable toxicities/AEs, disease progression ,withdraw their consent, or the investigator decides to discontinue the patient, or study cut-off, whichever comes first.
- a 30-day follow-up visit after the last dose of study medication.
The cut off date is when the last patient treated has completed cycle 1 and the subsequent 30 days follow-up.
Patients may continue to be treated as long as they are benefiting from study treatment and have not met study withdrawal criteria.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- Investigational Site Number 840014
-
Loma Linda, California, United States, 92354
- Investigational Site Number 840013
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- Investigational Site Number 840020
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Investigational Site Number 840016
-
Tampa, Florida, United States, 33612
- Investigational Site Number 840002
-
-
Illinois
-
Decatur, Illinois, United States, 62526
- Investigational Site Number 840017
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Investigational Site Number 840003
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Investigational Site Number 840019
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Investigational Site Number 840012
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Investigational Site Number 840001
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Investigational Site Number 840021
-
Cincinnati, Ohio, United States, 45267-0542
- Investigational Site Number 840007
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- Investigational Site Number 840010
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Investigational Site Number 840006
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients with a diagnosis of advanced, measurable or non-measurable, non-hematological cancer who have varying degrees of hepatic impairment. The cancer must be one that is either refractory to standard therapy or for which no standard therapy exists.
Exclusion criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) >2
- Life expectancy <3 months
- Need for a major surgical procedure or radiation therapy during the study
- Evidence of another active malignancy
- Prior chemotherapy, other investigational drug, biological therapy, targeted non-cytotoxic therapy and radiotherapy within 3 weeks prior to registration
- Patients with known history of Gilbert's syndrome
- Prior treatment with Cabazitaxel and a history of severe (Grade ≥3) hypersensitivity to taxanes, polysorbate-80, or to compounds with similar chemical structures
- Prior history of bone marrow transplant
- Any treatment known to induce CYP isoenzymes or to inhibit CYP3A4 activities within 2 weeks before or during the test period of the pharmacokinetic sampling. Moderate inhibitors within one week prior and during the pharmacokinetic sampling.
- Any contra-indications to midazolam, according to the applicable labeling.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: normal hepatic function: cabazitaxel
cabazitaxel 25mg/m^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks). |
Pharmaceutical form:solution for infusion Route of administration: intravenous |
Experimental: Cohort 2: mild hepatic impairment : cabazitaxel
cabazitaxel 20mg/m^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks). |
Pharmaceutical form:solution for infusion Route of administration: intravenous |
Experimental: Cohort 3: moderate hepatic impairment: cabazitaxel
cabazitaxel 10mg/m^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks). |
Pharmaceutical form:solution for infusion Route of administration: intravenous |
Experimental: Cohort 4: severe hepatic impairment: cabazitaxel
cabazitaxel 5 mg/m^2 or 10mg/m^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks). |
Pharmaceutical form:solution for infusion Route of administration: intravenous |
Experimental: Cohort 5: normal hepatic function: cabazitaxel and midazolam
cabazitaxel 25mg/m^2 IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks). Midazolam is given orally in single dosing on day -1 and day 1 (crossover) |
Pharmaceutical form:solution for infusion Route of administration: intravenous |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Dose Limiting Toxicities (DLT)
Time Frame: cycle 1 (3 weeks)
|
A clinical adverse event or a laboratory abnormality is defined as DLT when it is drug-related as assessed by the investigator and agreed upon by the study committee.
|
cycle 1 (3 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety investigations (physical examination, vital signs and laboratory tests)
Time Frame: up to 30 days after the last dosing
|
Physical examination includes Eastern Cooperative Oncology Group (ECOG) performance status and signs and symptoms. Vital signs includes weight, temperature, blood pressure and heart rate. Laboratory tests includes hematology, coagulation, biochemistry and urinalysis. Laboratory abnormalities are graded according to the NCI CTCAE v.4.0 |
up to 30 days after the last dosing
|
Pharmacokinetic profile of Cabazitaxel (AUC, Cmax, t1/2, CL, and Vss) from plasma concentration
Time Frame: cycle 1 (3 weeks)
|
cycle 1 (3 weeks)
|
|
Cabazitaxel effect on CYP3A enzyme activity
Time Frame: single dosing on day -1 and day 1
|
single dosing on day -1 and day 1
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- POP6792
- U1111-1116-5845 (Other Identifier: UTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasm Malignant
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Neoplasm | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingRefractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
Clinical Trials on Cabazitaxel (XRP6258)
-
SanofiCompletedMalignant Solid Tumor - Malignant Nervous System NeoplasmUnited States, Canada
-
AIO-Studien-gGmbHSanofi; ClinAssess GmbHTerminatedBreast Cancer | Lung Cancer | Recurrent Brain Metastases | Progressive Brain MetastasesGermany
-
University of Alabama at BirminghamSanofiCompletedNon-small Cell Lung Cancer (NSCLC) | Metastatic NSCLC | Stage IV NSCLCUnited States
-
Dr Anjali ZarkarSanofiCompletedTransitional Cell CarcinomaUnited Kingdom
-
SanofiCompleted
-
SanofiCompletedGastric CancerKorea, Republic of
-
SanofiCompletedNeoplasm MalignantNetherlands, Belgium, Spain, Italy, United Kingdom
-
Hellenic Cooperative Oncology GroupSanofiCompleted
-
SanofiCompletedAdvanced Solid TumorFrance, Spain
-
SanofiCompletedNeoplasms, MalignantUnited States, Belgium, Denmark, Netherlands, Sweden